<DOC>
	<DOCNO>NCT00226707</DOCNO>
	<brief_summary>Topical steroid standard care Chronic Hand Dermatitis , long-term use associate adverse effect . This study ass efficacy safety pimecrolimus cream 1 % patient mild-to-moderate chronic hand dermatitis .</brief_summary>
	<brief_title>Pimecrolimus Cream 1 % Patients ( 18 Years Age Over ) With Mild Moderate Chronic Hand Dermatitis</brief_title>
	<detailed_description />
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Pimecrolimus</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<criteria>Patients outpatient baseline ( Day 1 ) Patients must 18 year age Patients must chronic hand dermatitis base upon clinical diagnosis mild moderate dermatitis target hand baseline , define Investigator 's Global Assessment score 2 ( mild ) 3 ( moderate ) . Patients must inform study procedure medication give write informed consent Women pregnant breastfeeding . Patients receive systemic corticosteroid ( i.e. , oral , intravenous , intraarticular , rectal , intramuscular ) within one month prior first application study medication . Patients receive phototherapy ( e.g. , UVB , PUVA ) systemic therapy ( e.g. , immunosuppressant , cytostatics ) know suspected effect hand dermatitis within least one month prior first application study medication . Patients receive pimecrolimus cream 1 % tacrolimus ointment 0.1 % 0.03 % within 14 day prior first application study medication . Patients treat topical therapy ( e.g. , tar , topical corticosteroid , Burrows solution soak ) know suspected effect hand dermatitis within 7 day prior first application trial medication . Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2008</verification_date>
	<keyword>Chronic hand dermatitis , pimecrolimus , dermatitis</keyword>
</DOC>